Philip Morris Prepares for Q2 Earnings Amidst Positive Momentum

Jul.17.2023
Tobacco giant Philip Morris is expected to report strong earnings fueled by IQOS and ZYN, despite margin challenges.

Shares of tobacco giant Philip Morris International Inc. (NYSE: PM) continued to show positive momentum on Wednesday, with the stock gaining 6% over the past month. Investors eagerly await the company's second quarter 2023 earnings report, which is scheduled to be released on Thursday, July 20, before the market opens. 

 

Revenue Expectations

Analysts are projecting that Philip Morris will report revenue of $8.6 billion for the second quarter of 2023. This estimate suggests a growth of 10% compared to the same period last year. In the first quarter of this year, the company's revenue saw a 3.5% year-over-year increase, reaching $8 billion. 

 

Earnings Forecast

Philip Morris has provided guidance for adjusted earnings per share (EPS) ranging from $1.42 to $1.47 for the second quarter of 2023. Analysts, on the other hand, estimate EPS of $1.47, which is higher than the $1.32 reported in the same quarter last year. The first quarter of 2023 saw a 4.4% decrease in adjusted EPS, amounting to $1.38. 

 

Strength in IQOS

Philip Morris is expected to benefit from the continued strength of its IQOS product, which has been gaining market share across various regions and showing a rise in adoption. The company noted in its first quarter report that as of March 31, there were approximately 25.8 million IQOS users. Furthermore, with the introduction of the IQOS ILUMA, the product category has experienced further growth, attracting an estimated 10 million users. ILUMA has dominated market volumes in countries like Japan, Switzerland, and Spain, accounting for over 85% of HTU (heated tobacco unit) volumes. Alongside promising growth in developed countries, PMI is witnessing encouraging expansion for IQOS in low and middle-income markets. 

 

Growth of ZYN

Philip Morris will also benefit from the growth of nicotine pouch brand ZYN, which it acquired through the Swedish Match acquisition. In the first quarter, ZYN witnessed a 47% increase in volume in the US. The company sees significant potential to expand distribution and velocity, referring to the number of ZYN cans sold per store per week. 

 

Margin Challenges

In the first quarter, Philip Morris faced challenges with its margins due to inflationary pressures and supply chain obstacles. These pressures are expected to persist through the year, impacting the company's margins. Despite this, Philip Morris continues to make growth investments to support its business expansion. 

 

Investors are eager to see the financial results of Philip Morris International Inc. as the company prepares to release its second quarter 2023 earnings report. With expectations of revenue growth and increased earnings per share, fueled by the robust performance of IQOS and the potential of ZYN, Philip Morris appears to be well-positioned to meet market expectations. However, challenges with margins and inflationary pressures remain an ongoing concern.

This document has been generated through artificial intelligence translation and is provided solely for the purposes of industry discourse and learning. Please note that the intellectual property rights of the content belong to the original media source or author. Owing to certain limitations in the translation process, there may be discrepancies between the translated text and the original content. We recommend referring to the original source for complete accuracy. In case of any inaccuracies, we invite you to reach out to us with corrections. If you believe any content has infringed upon your rights, please contact us immediately for its removal.

Lancet Study Finds Rising Use of Nicotine Pouches in Britain
Lancet Study Finds Rising Use of Nicotine Pouches in Britain
A study published in The Lancet has found that nicotine pouch use is increasing in Britain, particularly among young men. Usage among people aged 16 to 24 has risen sharply since early 2022.
Dec.17 by 2FIRSTS.ai
Russia’s Federation Council Approves Law Allowing Extrajudicial Blocking of Online Tobacco Sales
Russia’s Federation Council Approves Law Allowing Extrajudicial Blocking of Online Tobacco Sales
Russia’s Federation Council has approved legislation allowing authorities to block websites offering online sales of tobacco, nicotine-containing products, heated tobacco devices and hookahs without a court order.
Dec.26 by 2FIRSTS.ai
Japan Tobacco Unveils New Ploom EVO Honey Lemon Smoke Stick, Nationwide Launch in Japan from January 2026
Japan Tobacco Unveils New Ploom EVO Honey Lemon Smoke Stick, Nationwide Launch in Japan from January 2026
Japan Tobacco (JT) has announced a new flavor for its Ploom brand’s premium EVO smoke sticks: “EVO Honey Lemon Crystal.” The product will be rolled out in stages, beginning with an early release through official channels in December 2025, followed by a nationwide launch across convenience stores and tobacco retailers in January 2026, priced at JPY 550 (approximately USD 3.7).
Dec.16 by 2FIRSTS.ai
Mongolia Proposes Full Regulation of E-Cigarettes Under Tobacco Law
Mongolia Proposes Full Regulation of E-Cigarettes Under Tobacco Law
Mongolia’s Parliament has begun reviewing major amendments to the Tobacco Control Law, which would bring e-cigarettes and other new nicotine products under the same legal framework as traditional cigarettes. The bill also proposes a gradual increase in tobacco excise taxes through 2030 and new restrictions on flavors, marketing, and public smoking.
Nov.26 by 2FIRSTS.ai
UK’s Nationwide Crackdown Seizes 111,000 Illegal Vapes in “Machinize 2” Operation
UK’s Nationwide Crackdown Seizes 111,000 Illegal Vapes in “Machinize 2” Operation
UK police have carried out a nationwide crackdown under Operation Machinize 2, targeting illegal vapes, counterfeit goods, and grey-market businesses. Raids on more than 2,700 premises led to 924 arrests and the seizure of 111,000 illegal vapes, 70kg of cannabis, 4.5m cigarettes, and £10.7m in proceeds.
Nov.11 by 2FIRSTS.ai
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
U.S. FDA Unveils Next-Generation Agentic AI Tool to Boost Review and Regulatory Efficiency
The U.S. FDA has announced the agency-wide deployment of new agentic AI capabilities, providing all employees with an optional multi-step task automation tool. Building on the broad adoption of its earlier large-language-model system, Elsa, the FDA aims to use this next-generation AI workflow to accelerate product review, regulatory oversight, and internal operations, while maintaining strict human supervision and data security.
Dec.02 by 2FIRSTS.ai